Sorivudine: A potent inhibitor of varicella zoster virus replication

Advances in Experimental Medicine and Biology

Volumn 394, Issue , 1996, Pages 41-44

  Whitley, Richard J ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BVARAK; SORIVUDINE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; HERPES ZOSTER; HUMAN; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VARICELLA ZOSTER VIRUS;

GALLUS GALLUS; HERPES; HERPES ZOSTER; HUMAN HERPESVIRUS 3;

EID: 0029982013     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4757-9209-6_5     Document Type: Conference Paper

References (11)

1. Machida H., Sakata S, Kuninaka A. Yoshino H. Antiherpesviral and anticellular effects of 1-b-D-arabinofuranosyl-E-5-(2-halogenovinyl) uracil. Antimicrob Agents Chemother. 1981;20:47-52.
2. b-D-arabinofuranosy-E-5-(2-bromovinyl) uracil (BV-araU) and related compounds. Antiviral Res. 1984;4:135-41.
3. Machida H. Comparison of susceptibilities of varicella-zoster virus and herpes simplex virus to nucleoside analogs. Antimicrob Agents Chemother. 1986;29:524-6.
4. Suzutani T, Machida H, Sakuma T, Azuma M. Effects of various nucelosides on antiviral activity and metabolism of 1-b-D-arabinofuranosyl-E-5-(2-bromovinyl) uracil against herpes simplex virus types 1 and 2. Antimicrob Agents Chemother. 1988;32:1547-51.
5. Cheng, Y-C, Dutschman G, Fox JJ, Watanabe KA, Machida H. Differential activity of potential antiviral nucleoside analogs on herpes simplex virus-induced and human cellular thymidine kinases. Antimicrob Agents Chemother. 1981;20:420-3.
6. Yokota T, Kono K, Mori S, Shigeta S, Kumagai M, Watanabe Y, Machida H. Mechanism of selective inhibition of varicella-zoster virus replication by 1-b-D-arabinofuranosyl-E-5-(2-bromovinyl) uracil. A report from Yamasa Shoyu Co., Japan, 1988.
7. Soike KF, Baskin G, Cantrell C, Gerone P. Investigation of antiviral activity of 1-b-D-arabinofuranosylthymine (ara-T) and 1-b-D-arabinofuranosyl-E-5-(2-bromovinyl) uracil (BV-araU) in monkeys infected with simian varicella virus. Antiviral Res 1984;4:245-57.
8. Whitley RJ, Weiss H, Gnann J, et al. Sorivudine (BV-araU) versus acyclovir for herpes zoster in HIV-infected patients: Results of a multi-center controlled trial. Presented at the Clinical Research Meeting. San Diego, CA, May 5-8, 1995. J Invest Med 1995;43:A114.
9. Wallace MR, Sawyer MH, Chamberlin CJ, Hawkins J, Oldfield III EC. BV-aru-U for the treatment of adult varicella. Presented at the Second International Conference on Varicella Zoster Virus Infections. Paris, France. 1994, July 7 and 8.
10. DeHertog D, et al. Sorivudine (BV-araU) versus acyclovir for herpes zoster in HIV-infected patients: Results of a multi-center controlled trial. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, Florida, October 4-7, 1994. Late breaker.
11. Yawata M. Deaths due to drug interaction. Lancet 1993;342:1166.